MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

NephroGenex Company Profile (NASDAQ:NRX)

Consensus Ratings for NephroGenex (NASDAQ:NRX) (?)
Ratings Breakdown: 2 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $14.50 (10,249.75% upside)

Analysts' Ratings History for NephroGenex (NASDAQ:NRX)
Show:
DateFirmActionRatingPrice TargetActions
4/15/2016Rodman & RenshawReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/8/2016HC WainwrightDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/17/2015MLV & Co.Reiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/31/2014AegisReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for NephroGenex (NASDAQ:NRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/11/2016        
11/11/2015Q315($0.65)($0.53)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.56)($0.72)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q115($0.62)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2015Q414($0.58)($0.60)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q314($0.46)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.24)($0.61)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014Q114($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for NephroGenex (NASDAQ:NRX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for NephroGenex (NASDAQ:NRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for NephroGenex (NASDAQ:NRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/6/2015Ventures V L.P. RhoMajor ShareholderSell273,860$10.58$2,897,438.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Bob PetersonVPBuy2,000$4.20$8,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Robert R SeltzerDirectorBuy790,000$12.00$9,480,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for NephroGenex (NASDAQ:NRX)
DateHeadline
06/28/16 10:21 AMNext Weeks Broker Price Targets For NephroGenex, Inc. (NRX) - Fiscal Standard
06/25/16 09:14 AMNew Broker Ratings For NephroGenex, Inc. (NRX) - FTSE News
05/30/16 09:02 PMNext Weeks Broker Price Targets For NephroGenex, Inc. (NRX) - Share Trading News - Next Weeks Broker Price Targets For NephroGenex, Inc. (NRX)Share Trading NewsNephroGenex, Inc. has a 50 day moving average of 0.40 and a 200 day moving average of 1.17. It has a 52-week low of 0.10 and a 52-week high of 8.90. The share price of the company (NRX) was up +0.00%, with a high of 0.00 during the day and the ...
05/27/16 01:37 PMNephroGenex, Inc. (NASDAQ:NRX) Closes At $0.1401 - RealistInvestor.com - NephroGenex, Inc. (NASDAQ:NRX) Closes At $0.1401RealistInvestor.comThe technical analysis of NephroGenex, Inc. (NASDAQ:NRX) stock highlights the stock is $-0.2628 points away -65.2234% from its 50-day MA of $0.4029. It is $-1.0265 or -87.9909% away $1.1666, the 200-day Moving Average (MA) of stock. Yesterday, the ...
05/02/16 01:37 PM3 Companies Filed For Chapter 11 Bankruptcy Today - Monday's trading action featured at least three companies filing for Chapter 11 bankruptcy. NephroGenex NephroGenex Inc (NASDAQ: NRX), a pharmaceutical company that focuses on the development of treatment for kidney disease, announced it has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code. "The Board and management team have conducted a rigorous assessment of all of our strategic alternatives and believe that this process represents the best possible solution for NephroGenex, taking into account our financial situation," said Richard J. Markham, chairman of the board of NephroGenex. "We are committed to an outcome that maximizes value and believe that a bankruptcy sale process will enable us to meet that objective." Related Link: SunEdison Confirms It Has Filed ...Full story available on Benzinga.com
05/02/16 08:43 AMNephroGenex Files For Bankruptcy Protection Under Chapter 11 -
05/02/16 07:20 AMNephroGenex, Inc. Commences Voluntary Chapter 11 Proceeding; Seeks To Initiate Sale Process Under Section 363 - [at noodls] - RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that it filed a voluntary petition ...
04/26/16 02:00 PMResearch Triangle area's biotech sector in steep bear market -
04/14/16 03:30 PMHow NephroGenex went from darling to disaster -
04/08/16 06:10 AMNephroGenex downgraded by H.C. Wainwright -
03/31/16 01:46 AMNATUREX - FY 2015 Results - [PR Newswire] - PARIS, March 31, 2016 /PRNewswire/ -- NATUREX, the world leader in natural ingredients, reports 2015 full year results. CEO Olivier Rigaud comments on results and outlook. Watch video interview and read ...
02/26/16 12:40 PMNephroGenex restructuring; INC forecasts $1B in revenue; PRA reports major growth - Durham-based life science firm NephroGenex (Nasdaq: NRX) has stopped a clinical research program for ... NephroGenex says it has $11.5 million in cash and eqivalents. INC Research eyes $1 billion in revenue INC research (nasdaq: INCR) is forecasting ...
02/24/16 03:31 PMNEPHROGENEX, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Costs Associated with Exit or D -
02/24/16 02:16 PMHere's Why NephroGenex Plunged 40% On Wednesday - Shares of NephroGenex Inc (NASDAQ: NRX), a nano-cap pharmaceutical company that focuses on treatment for kidney diseases, plunged more than 40 percent on Wednesday after the company announced a business update. NephroGenex said it ...Full story available on Benzinga.com
02/24/16 10:24 AMNephroGenex stock tumbles after announcement to halt trial over consideration of reverse merger -
02/24/16 08:20 AMNephroGenex Provides Corporate Update - [Business Wire] - NephroGenex, Inc. , a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that its Board of Directors has made a determination to pause the clinical program of the Company’s product candidate oral Pyridorin® for the treatment of diabetic nephropathy, effect a restructuring of its operations, and implement a strategic transaction.
02/24/16 06:07 AMQ4 2015 NephroGenex Inc Earnings Release - After Market Close -
02/16/16 07:00 AMNephroGenex to Host Conference Call and Webcast on Fourth Quarter and Full Year 2015 Financial Results on Thursday, February 25, 2016 - [Business Wire] - NephroGenex, Inc. , a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report its fourth quarter and full year 2015 financial results on Wednesday, February 24 after the U.S.
02/07/16 01:32 PMLatest Analysts Reports On NephroGenex, Inc. (NRX) - Risers & Fallers - Latest Analysts Reports On NephroGenex, Inc. (NRX)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of NephroGenex, Inc. (NRX). The latest broker reports which have been released state 0 analysts have a rating of “buy”, 1 analysts “outperform”, 0 analysts “hold”, 0 analysts ...
02/04/16 02:00 PMDaily Watch List: NephroGenex (NASDAQ:NRX), Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP), Crescent Point ... - Property Mentor - Daily Watch List: NephroGenex (NASDAQ:NRX), Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP), Crescent Point ...Property MentorAlphabet Inc (NASDAQ:GOOG) caters to the Technology space. Its weekly performance is 3.85%. On the last day of trading company shares ended up at $726.95. Alphabet Inc (NASDAQ:GOOG) distance from 50-day simple moving average (SMA50) is 1.37% ...and more »
01/29/16 01:23 PMNephroGenex, Inc. (NASDAQ:NRX) Short Interest Update - The Daily Rover - NephroGenex, Inc. (NASDAQ:NRX) Short Interest UpdateThe Daily RoverNephroGenex, Inc. (NASDAQ:NRX) stated gains of 123,895 shares or 33.4% in the short interest. The short interest registered from 370,464 on December 31,2015 to 494,359 on January 15,2016. In terms of floated shares, the shorted positions stood at 7.4%.
01/27/16 12:43 PMNephroGenex to Present at the 18th Annual BIO CEO & Investor Conference - Business Wire (press release) - NephroGenex to Present at the 18th Annual BIO CEO & Investor ConferenceBusiness Wire (press release)RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that CEO and President Pierre Legault will present a corporate ...and more »
01/27/16 07:26 AMNephroGenex to Present at the 18th Annual BIO CEO & Investor Conference - [at noodls] - RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that CEO and President Pierre ...
01/26/16 01:19 PMNephroGenex, Inc. Analyst Rating Update - WallStreet Prudent - NephroGenex, Inc. Analyst Rating UpdateWallStreet PrudentAnalysts at Zacks Investment Research have given a short term rating of hold on NephroGenex, Inc. (NASDAQ:NRX) with a rank of 3. The shares have received an average rating of 1 from 1 brokerage firms. 1 analysts have rated the company as a strong buy.and more »
01/25/16 12:36 PMCompany Shares of NephroGenex, Inc. (NASDAQ:NRX) Drops by -9.82% - Market Briefing - Company Shares of NephroGenex, Inc. (NASDAQ:NRX) Drops by -9.82%Market BriefingNephroGenex, Inc. (NASDAQ:NRX) has lost 9.82% during the past week and dropped 40.24% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 11.08%. NephroGenex, Inc. (NASDAQ:NRX) ...Stock Runners: NephroGenex, Inc. (NASDAQ:NRX), Erin Energy Corporation (NYSEMKT:ERN), Automatic Data ...Benchmark MonitorHealthcare Stocks in Focus: Rockwell Collins Inc. (NYSE:COL), Cigna Corp. (NYSE:CI), NephroGenex, Inc. (NASDAQ ...Seneca GlobeNephroGenex Receives a Buy from Rodman & RenshawMarkets.coall 4 news articles »
01/24/16 11:45 AMNephroGenex Receives a Buy from Rodman & Renshaw - Markets.co - NephroGenex Receives a Buy from Rodman & RenshawMarkets.coRodman & Renshaw analyst Yi Chen reiterated a Buy rating on NephroGenex (NASDAQ: NRX) on January 22 and set a price target of $9. The company's shares closed last ... NephroGenex Inc is a drug development company. The Company is engaged in ...
01/24/16 11:45 AM3 Stocks Jumping on Abnormally High Volume: Cardica, Inc. (CRDC), NephroGenex Inc (NRX), Synergy Resources ... - Street Register - 3 Stocks Jumping on Abnormally High Volume: Cardica, Inc. (CRDC), NephroGenex Inc (NRX), Synergy Resources ...Street RegisterNephroGenex Inc (NRX) announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's pivotal Phase 3 study of oral Pyridorin® for the treatment of diabetic nephropathy has completed the second, pre-planned six-month safety ...
01/22/16 07:38 PMAMGN Gets FDA Nod, Data Awaits RGLS In Feb, FORWARD Puts ALKS On The Back Foot - Nasdaq - AMGN Gets FDA Nod, Data Awaits RGLS In Feb, FORWARD Puts ALKS On The Back FootNasdaqNephroGenex Inc.'s (NRX) oral drug candidate Pyridorin for the treatment of diabetic nephropathy, which is under a pivotal phase III study, has been deemed to have a continued acceptable safety and tolerability profile in the second review by the ...and more »
01/22/16 07:38 PMPre-Open Stock Movers 01/22: (NRX) (EGHT) (CHK) Higher; (CSII) (LGCY) (DGII) Lower (more...) - StreetInsider.com - StreetInsider.comPre-Open Stock Movers 01/22: (NRX) (EGHT) (CHK) Higher; (CSII) (LGCY) (DGII) Lower (more...)StreetInsider.comNephroGenex, Inc. (Nasdaq: NRX) 27% HIGHER; announced that the independent Data and Safety Monitoring Board (DSMB) for the Companys pivotal Phase 3 study of oral Pyridorin for the treatment of diabetic nephropathy has completed the second, ...
01/22/16 07:38 PMNephroGenex (NRX) Reports IDSMB Recommendation to Continue Oral Pyridorin Phase 3 as Planned - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. NephroGenex, Inc. (Nasdaq: NRX) announced that the independent Data and Safety Monitoring Board (DSMB) for the Company’s pivotal Phase 3 study of oral Pyridorin for the ...
01/21/16 07:49 PMNephroGenex (NRX) Reports IDSMB Recommendation to Continue Oral Pyridorin ... - StreetInsider.com - NephroGenex (NRX) Reports IDSMB Recommendation to Continue Oral Pyridorin ...StreetInsider.comNephroGenex, Inc. (Nasdaq: NRX) announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's pivotal Phase 3 study of oral Pyridorin for the treatment of diabetic nephropathy has completed the second, pre-planned ...NephroGenex Announces Independent DSMB Recommendation to Continue Phase 3 ...PharmiWeb.com (press release)all 3 news articles »
01/21/16 03:39 PMNephroGenex Announces Independent DSMB Recommendation to Continue Phase 3 Study of Oral Pyridorin in Diabetic Nephropathy Without Modification - [at noodls] - RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that the independent Data and ...
01/21/16 03:11 PM4:11 pm NephroGenex announces independent DSMB recommendation to continue Phase 3 study of oral Pyridorin in diabetic nephropathy without modification -
01/07/16 03:03 PMNEPHROGENEX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
01/06/16 07:00 AMNephroGenex to Participate in Two Healthcare Conferences in January - [Business Wire] - NephroGenex, Inc. , a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that CEO and President Pierre Legault will present a corporate overview of the Company at two upcoming healthcare conferences in January.
01/05/16 07:00 AMNephroGenex Announces Formation of Scientific Advisory Board - [Business Wire] - NephroGenex, Inc. , a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the appointment of leading experts in nephrology to its newly formed Scientific Advisory Board .
12/14/15 04:40 PMRaleigh drug developer sees shares soar on good news from FDA -
12/14/15 02:58 PMWhy Are Investors Piling Into These Stocks? -
12/14/15 11:52 AMThanks, FDA: NephroGenex Investors Rejoice After New Clearance -
12/14/15 10:29 AMNephroGenex (NRX) Stock Soars After FDA Approves Clinical Trials for Kidney Treatment -
12/14/15 07:00 AMNephroGenex Announces FDA Clearance of IND Application for Clinical Study of Intravenous Pyridorin in the Treatment of Acute Kidney Injury - [Business Wire] - NephroGenex, Inc. , a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for clinical studies with intravenous Pyridorin® for the treatment of acute kidney injury.
12/08/15 12:18 PMNEPHROGENEX, INC. Financials -
11/13/15 06:14 AMNEPHROGENEX, INC. Files SEC form 8-K, Financial Statements and Exhibits -
11/11/15 03:16 PMNephroGenex Reports Third Quarter 2015 Financial Results - [at noodls] - RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business ...
About NephroGenex

NephroGenex logoNephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company is engaged in the development of Pyridorin (pyridoxamine dihydrochloride). Pyridorin targets the pathogenic oxidative chemistries that emerge in diabetic patients and lead to kidney disease. The Company's product pipeline includes oral Pyridorin and intravenous (I.V.) Pyridorin. Oral Pyridorin is under development as a treatment for slowing the progression of diabetic nephropathy due to type 2 diabetes. I.V. formulation of Pyridorin is under development for the treatment of specific types of acute kidney injury (AKI). Pyridorin has received Fast Track Designation from the United States Food and Drug Administration (FDA), for the treatment of Diabetic Nephropathy.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NRX
  • CUSIP:
Key Metrics:
  • Previous Close: $0.14
  • 50 Day Moving Average: $0.4029
  • 200 Day Moving Average: $1.1666
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $N/A
  • Current Quarter EPS Consensus Estimate: $-0.3000 EPS
Additional Links:
NephroGenex (NASDAQ:NRX) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha